Company patents

Cytokinetics, Inc.

Cytokinetics, Inc. demonstrates a strong and consistent focus on core pharmaceutical innovation, with Heterocyclic Compounds representing a dominant 79.3% of its portfolio. While patenting in Pharmaceutical Preparations saw an impressive 83.3% YoY growth in 2025, the significant year-over-year declines across most categories so far in 2026, such as an 81.8% drop in Pharmaceutical Preparations and a 69.2% decline in Heterocyclic Compounds, suggest a potential shift in patenting strategy or a natural fluctuation given that 2026 data is partial.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

58 US filings (since 2023) · 7 categories · 7 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical PreparationsAcyclic / Carbocyclic Compounds
Who else files here? →
46since 2023
-12.5%YoY
API Solid Form Engineering

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
11since 2023
-25.0%YoY
Advanced Drug Delivery Systems

Development of lipid-based nanoparticles, liposomes, or other molecular platforms to encapsulate and deliver therapeutic agents, particularly nucleic acids, to target tissues or improve pharmacokinetics.

Acyclic / Carbocyclic Compounds
Who else files here? →
5since 2023
+100.0%YoY
Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

Heterocyclic Compounds (Pharma)
Who else files here? →
4since 2023
-50.0%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
3since 2023
0.0%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Therapeutic Activity (Pharma)
Who else files here? →
2since 2023
n/a
Adaptive & Wearable Bio-Stimulation

Systems that provide therapeutic stimulation or field therapy through wearable devices, often incorporating physiological sensing and closed-loop feedback for personalized and adaptive treatment.

Electrotherapy / Radiation Therapy
Who else files here? →
1since 2023
new

Patents

Showing 21-30 of 176

Page 3 of 18